Chandan Healthcare Ltd IPO

Any interruptions at its flagship diagnostic centres may affect the company ability to process diagnostic tests, which in turn may adversely affect its business, results of operations and financial condition.

The company business and prospects may be adversely affected if its unable to maintain and grow the company brand name and brand image.

The company is dependent on B2C and few other customers for a major part of its revenues. Further the company does not enter long-term arrangements with its customers and any failures to continue the company existing arrangements could adversely affect its business and results of operations.

Any non-renewal or cancellation of its arrangements with the company institutional customers, including hospitals, and government agencies may adversely affect its business, results of operations and financial condition.

The company operations are only focused on Uttar Pradesh and Uttarakhand, and any loss of business in such region could have an adverse effect on its business, results of operations and financial condition.

The company primary source of revenue is from its pathology and radiology services and the company business may be adversely affected if these categories does not perform as well as expected.

The company is dependent on its Group Company for a significant part of the company revenues. Further the company has not entered into any long-term arrangements with its group company i.e. Chandan Hospital Limited and any failures to deliver the commitment could adversely affect its business and results of operations.

The company relies on domestic suppliers for the supply of medical consumables particularly suppliers from Uttar Pradesh and any delay, interruption or reduction in such supply could adversely affect its business, results of operations, financial condition and cash flows.

The company contingent liabilities as stated in its Restated Financial Statements could affect the company financial condition.

The company depends on third parties to provide it reagents and films, and any failures to continue to do so or recall of existing testing equipment and reagents could adversely affect its business, results of operations and financial condition.